Infectious Diseases in Obstetrics and Gynecology / 2012 / Article / Tab 1

Research Article

Progress towards Elimination of HIV Mother-to-Child Transmission in the Dominican Republic from 1999 to 2011

Table 1

Characteristics of maternal HIV diagnosis, maternal and infant antiretroviral use, mode of delivery and infant feeding, Dominican Republic, 1999–2008, and 2009–2011.

Diagnosis and management1999–20082009–2011
No. (%)No. (%)
N = 1,274N = 302

Time of HIV diagnosis
 Before pregnancy277 (21.7)77 (25.5)
 During pregnancy617 (48.4)143 (47.4)
 Labor/delivery73 (5.7)38 (12.6)*
 ≤72 hours post-partum66 (5.2)5 (1.7)*
 After 72 hours160 (12.6)38 (12.6)
 Unknown81 (6.3)1 (0.3)*

Maternal antiretroviral use
 Any868 (68.1)265 (87.7)*
  HAART, either157 (12.3)205 (67.9)*
   AZT + 3TC + NVP1157 (12.3)59 (19.5)
   AZT-3TC-Lop2146 (48.3)*
  Multidose AZT19 (1.5)0
  Multidose AZT + 3TC61 (4.8)
  Single dose NVP3503 (39.5)60 (19.5)*
 Received no ARVs406 (31.9)37 (12.2)*
 Unknown121 (9.5)0*

Type of delivery
 Vaginal285 (22.4)81 (26.8)
 All Caesareans882 (69.2)199 (65.9)
  Elective caesarian882 (69.2)152 (50.3)
  Emergency caesarean 47 (15.6)
 Unknown107 (8.4)22 (7.3)

Infant nutrition
 Formula only972 (76.3)260 (86.1)*
 Breast feeding only67 (5.3)4 (1.3)*
 Both43 (3.4)13 (4.2)
 Unknown192 (15.1)25 (8.3)*

Infant antiretrovirals (ARVs)
 Started between 8–72 hours782 (61.4)184 (60.9)
  Multidose AZT81 (6.4)126 (41.7)*
  Single-dose NVP only701 (55.0) 58 (19.3)*
 Did not receive ARVs219 (17.2)74 (24.6)*
 Unknown273 (21.4)44 (14.5)*

* P < .01 by time period.
1Zidovudine, lamivudine, nevirapine highly active antiretroviral therapy.
2Zidovudine, lamivudine, ritonavir-boosted lopinavir highly active antiretroviral therapy.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.